Last reviewed · How we verify
A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of LIM-0705 Given With or Without Tacrolimus in Healthy Male Subjects
LIM-0705 dosed separately and in combination with tacrolimus will be safe and well tolerated.
Details
| Lead sponsor | Limerick BioPharma |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 44 |
| Start date | 2010-02 |
| Completion | 2010-06 |
Conditions
- Healthy
Interventions
- LIM-0705 and tacrolimus
- LIM-0705 and tacrolimus
- Placebo LIM-0705 and tacrolimus
- Drug LIM-0705 and placebo tacrolimus
Primary outcomes
- Safety and tolerability of LIM-0705 with and without co-administered drug (tacrolimus). — 14 days
Countries
Australia